Esperion


Chardan Raises Price Target For Esperion Therapeutics Inc, But Remains Cautious

In a research report released Friday, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR) and raised the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts